Therefore, OBP-702-mediated tumor-specific p53 activation may be a more useful strategy than conventional therapies to increase sensitivity to p53-targeting CTLs induced by Ad-p53 DC vaccine therapy. This evidence concerns the gene TP53 and neoplasm.